Literature DB >> 32146606

Development of oncolytic virotherapy: from genetic modification to combination therapy.

Qiaoshuai Lan1, Shuai Xia1, Qian Wang1, Wei Xu1, Haiyan Huang2, Shibo Jiang3,4, Lu Lu5.   

Abstract

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

Entities:  

Keywords:  chimeric antigen receptor T cell; genetic modification; immune checkpoint blockade; immunotherapy; oncolytic virus

Mesh：

Year:  2020        PMID： 32146606      PMCID： PMC7101593          DOI： 10.1007/s11684-020-0750-4

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   4.592


  237 in total

1.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

Authors:  J A McCart; J M Ward; J Lee; Y Hu; H R Alexander; S K Libutti; B Moss; D L Bartlett
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 2.  Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.

Authors:  Claud Grigg; Zoë Blake; Robyn Gartrell; Adrian Sacher; Bret Taback; Yvonne Saenger
Journal:  Semin Oncol       Date:  2016-10-27       Impact factor: 4.929

3.  Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Authors:  Laetitia Fend; Takahiro Yamazaki; Christelle Remy; Catherine Fahrner; Murielle Gantzer; Virginie Nourtier; Xavier Préville; Eric Quéméneur; Oliver Kepp; Julien Adam; Aurélien Marabelle; Jonathan M Pitt; Guido Kroemer; Laurence Zitvogel
Journal:  Cancer Res       Date:  2017-05-23       Impact factor: 12.701

4.  MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.

Authors:  Praveen K Bommareddy; Salvatore Aspromonte; Andrew Zloza; Samuel D Rabkin; Howard L Kaufman
Journal:  Sci Transl Med       Date:  2018-12-12       Impact factor: 17.956

Review 5.  Zika virus: history of a newly emerging arbovirus.

Authors:  Nitwara Wikan; Duncan R Smith
Journal:  Lancet Infect Dis       Date:  2016-06-06       Impact factor: 25.071

6.  Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment.

Authors:  M Garofalo; H Saari; P Somersalo; D Crescenti; L Kuryk; L Aksela; C Capasso; M Madetoja; K Koskinen; T Oksanen; A Mäkitie; M Jalasvuori; V Cerullo; P Ciana; M Yliperttula
Journal:  J Control Release       Date:  2018-06-01       Impact factor: 9.776

7.  Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.

Authors:  Eike Binz; Susanne Berchtold; Julia Beil; Martina Schell; Christine Geisler; Irina Smirnow; Ulrich M Lauer
Journal:  Mol Ther Oncolytics       Date:  2017-04-19       Impact factor: 7.200

Review 8.  Oncolytic Viral Therapy for Mesothelioma.

Authors:  Daniel F Pease; Robert A Kratzke
Journal:  Front Oncol       Date:  2017-08-24       Impact factor: 6.244

Review 9.  Prospects for combined use of oncolytic viruses and CAR T-cells.

Authors:  Adam Ajina; John Maher
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

10.  A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.

Authors:  Valerio Leoni; Andrea Vannini; Valentina Gatta; Julie Rambaldi; Mara Sanapo; Catia Barboni; Anna Zaghini; Patrizia Nanni; Pier-Luigi Lollini; Costanza Casiraghi; Gabriella Campadelli-Fiume
Journal:  PLoS Pathog       Date:  2018-08-06       Impact factor: 6.823
View more
  9 in total

1.  Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study.

Authors:  Jing Zhang; Qiying Zhang; Zi Liu; Juan Wang; Fan Shi; Jin Su; Tao Wang; Fei Wang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

Review 2.  Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.

Authors:  Chao Tang; Lan Li; Tong Mo; Jintong Na; Zhangbo Qian; Dianfa Fan; Xinjun Sun; Min Yao; Lina Pan; Yong Huang; Liping Zhong
Journal:  Clin Transl Oncol       Date:  2022-05-25       Impact factor: 3.340

3.  Multiomic Profiling Identified EGF Receptor Signaling as a Potential Inhibitor of Type I Interferon Response in Models of Oncolytic Therapy by Vesicular Stomatitis Virus.

Authors:  Anastasia S Nikitina; Anastasia V Lipatova; Anton O Goncharov; Anna A Kliuchnikova; Mikhail A Pyatnitskiy; Ksenia G Kuznetsova; Azzam Hamad; Pavel O Vorobyev; Olga N Alekseeva; Marah Mahmoud; Yasmin Shakiba; Ksenia S Anufrieva; Georgy P Arapidi; Mark V Ivanov; Irina A Tarasova; Mikhail V Gorshkov; Peter M Chumakov; Sergei A Moshkovskii
Journal:  Int J Mol Sci       Date:  2022-05-08       Impact factor: 6.208

Review 4.  Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.

Authors:  Ke-Tao Jin; Wen-Lin Du; Yu-Yao Liu; Huan-Rong Lan; Jing-Xing Si; Xiao-Zhou Mou
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

Review 5.  Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.

Authors:  Ghazal Asadi Garmaroudi; Farzaneh Karimi; Leila Ghanbari Naeini; Pajman Kokabian; Nozar Givtaj
Journal:  Oxid Med Cell Longev       Date:  2022-07-22       Impact factor: 7.310

Review 6.  Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.

Authors:  Yi Ren; Jia-Meng Miao; Yuan-Yuan Wang; Zheng Fan; Xian-Bin Kong; Long Yang; Gong Cheng
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

Review 7.  Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.

Authors:  Zhongbing Qi; Xiangyu Long; Jiyan Liu; Ping Cheng
Journal:  Front Cell Neurosci       Date:  2022-09-09       Impact factor: 6.147

Review 8.  Nucleic Acid-Based Approaches for Tumor Therapy.

Authors:  Simone Hager; Frederic Julien Fittler; Ernst Wagner; Matthias Bros
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600

9.  Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.

Authors:  XuSha Zhou; Jing Zhao; Jian V Zhang; Yinglin Wu; Lei Wang; Xiaoqing Chen; Dongmei Ji; Grace Guoying Zhou
Journal:  Viruses       Date:  2021-09-03       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.